ANDRZEJ KRAUZE
In June of 2014, Pablo Meyer went to Rockefeller University in New York City to give a talk about open data. He leads the Translational Systems Biology and Nanobiotechnology group at IBM Research and also guides so-called DREAM challenges, or Dialogue for Reverse Engineering Assessments and Methods. These projects crowdsource the development of algorithms from open data to make predictions for all manner of medical and biological problems—for example, prostate cancer survival or how quickly ALS patients’ symptoms will progress. Andreas Keller, a neuroscientist at Rockefeller, was in the audience that day, and afterward he emailed Meyer with an offer and a request. “He said, ‘We have this data set, and we don’t model,’” recalls Meyer. “‘Do you think you could organize a competition?’”
The ...
